Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia

Yonsei Medical Journal

Volumn 47, Issue 5, 2006, Pages 706-714

  Park, Dong Soo ^a   Cho, Taek Woo ^a   Lee, Yong Kyu ^a   Lee, Young Tae ^a   Hong, Young Kwon ^a   Jang, Woong Ki ^a  

^a CHA University   (South Korea)

Author keywords

Benign prostatic hyperplasia; Botulinum toxin type A; Neurotransmitter

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; DOXAZOSIN; NITRIC OXIDE; PROSTATE SPECIFIC ANTIGEN; SODIUM CHLORIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ADRENERGIC ACTIVITY; ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FOLLOW UP; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; ORGAN SIZE; PENIS ERECTION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL URINE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY; URINE FLOW RATE; UROGENITAL SYSTEM PARAMETERS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSTATIC HYPERPLASIA; SULFONAMIDES;

EID: 33750695251     PISSN: 05135796     EISSN: 05135796     Source Type: Journal    
DOI: 10.3349/ymj.2006.47.5.706     Document Type: Article

References (21)

1. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986;136:1-4.
2. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994;44:692-9.
3. McConnell JD, Bruskewitz R, Walsh P, Andriloe G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1999;338:557-63.
4. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley C, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335: 533-9.
5. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998;37:44-50.
6. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259-65.
7. Dail WG. Autonomic innervation of male reproductive genitalia. In: Maggi CA, editor. Nervous Control of the Urogenital System. Switzerland, Harwood Academic Publishers; 1993. p.69-101.
8. Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000;20:193-206.
9. Bartsch C, Frick J, Ruegg I, Bucher M, Holliger O, Oberholzer M, et al. Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia, J Urol 1979;122:481-6.
10. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990,17:651-9.
11. Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002;94:93-112.
12. Lange W, Unger J. Peptidergic innervation within the prostate gland and seminal vesicle. Urol Res 1990;18: 337-40.
13. Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al. Pharmacological cbaracterization of isolated human prostate. J Urol 2003;170: 1032-8.
14. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995;45:440-6.
15. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985;134:1291-8.
16. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann. U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8.
17. Addicks K, Bloch W, Feelisch M. Nitric oxide modulates sympathetic neurotransmission at the prejunctional level. Microsc Res Tech 1994;29:161-8.
18. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of Botulinum neurotoxin. In: Jankovic J, Hallet M, editors. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994. p.3-13.
19. Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999;31:335-41.
20. Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 1997;63:115-26.
21. Hedlund P, Ny L, Alm P, Andersson KE. Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. J Urol 2000;164:868-75.